ATAD2 and endometrial carcinoma: Taken together, our findings support that immunohistochemical staining for ATAD2 represent a clinically applicable method to measure phenotype relevant ATAD2 level in endometrial carcinomas, also with the advantage of morphologic assessment during the IHC analysis.